I start by thanking my hon. Friend for his work in this important area. Regulators are working closely with industry to evaluate new dementia medicines, because of course we want patients to benefit from rapid access to safe and effective treatments. We are also strongly committed to funding dementia research, including doubling the amount allocated to £160 million a year by next year, and last year we launched the Dame Barbara Windsor dementia mission, backed up with new funding, which will work with industry to develop biomarkers and data and digital science innovations and to strengthen our trials in dementia. I look forward to hearing more suggestions from my hon. Friend on that.